Compare · BDX vs WOK
BDX vs WOK
Side-by-side comparison of Becton Dickinson and Company (BDX) and WORK Medical Technology Group LTD (WOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and WOK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 239399.8x WOK ($172,633).
- Over the past year, BDX is down 13.0% and WOK is down 100.0% - BDX leads by 87.0 points.
- WOK has been more active in the news (16 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 0 for WOK).
- Company
- Becton Dickinson and Company
- WORK Medical Technology Group LTD
- Price
- $150.14-0.71%
- $0.10+14.33%
- Market cap
- $41.33B
- $172,633
- 1M return
- -2.01%
- -92.32%
- 1Y return
- -12.95%
- -100.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 10
- 16
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest WOK
- Large owner Hrt Financial Lp bought $148,922 worth of shares (1,424,537 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 331,652 shares (SEC Form 3)
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
- Large owner Hrt Financial Lp bought $378,994 worth of shares (2,746,332 units at $0.14) and sold $188,101 worth of shares (1,757,955 units at $0.11) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 351,959 shares (SEC Form 3)
- WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
- SEC Form 3 filed by new insider Johnson Robert Brian
- Large owner Hrt Financial Lp bought $138,226 worth of shares (1,535,850 units at $0.09) and sold $261,961 worth of shares (2,619,607 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 225,234 shares (SEC Form 3)